Re: Alex 2 and S extended for 96 weeks
Clarification from BCRX regarding Stonehouse's comment on "trial usage":
He was referring to “trial” usage post 7353 regulatory approval in a sampling program. We will likely offer a “trial” period of some time so a patient can try the oral (7353) for free to get experience on the drug and the convenience of an oral.
Repost of what Stonehouse said:
Jon Stonehouse
I think, Alan, one other really important piece that we see in both, when we did this research a while back before the new therapies were on the market, and now with the new therapies on the market, is a consistency that patients want to try an oral. And so, I think our trial usage is going to be really high. We see that consistent with all the market research we've done. And so then it's a matter of what experience do they have on the drug and will they stay on it.
And we think that, if you do the simple math of looking at injections with something like TAKHZYRO, where you have an injection every two weeks, that's many injections over the course of the year versus if you have a breakthrough attack on your oral therapy and you got to inject Firazyr for example, it's way less. So we think that the trial usage is going to be very high and we think many patients are going to stay on therapy, because they don't want an injection.